Recombinant Oncolytic Virus Composition for Sustained Tumor Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing tumor treatment methods, including oncolytic viruses, fail to achieve continuous and efficient tumor killing, and combination therapies often result in suboptimal synergistic effects and high side effects.
Innovation Solution
A recombinant oncolytic virus composition comprising multiple herpes simplex virus vectors with different exogenous genes, such as cytokines and monoclonal antibodies, is developed to enhance tumor killing efficacy while minimizing side effects through precise gene expression control and balanced mixing ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If oncolytic virus is used for tumor treatment, then tumor cell lysis and death is achieved, but treatment efficiency is low and recurrence rate is high
Solution Approach 1:
The patent combines multiple oncolytic viruses with different exogenous genes into a composition, where each virus contributes different anti-tumor mechanisms (direct lysis, immune response enhancement, cytokine expression). This merging of multiple viral agents with complementary functions achieves both high killing efficiency and sustained anti-tumor effect, preventing recurrence
Solution Approach 2:
The invention creates a composite virotherapy system by formulating a composition containing multiple recombinant oncolytic viruses. Each virus in the composition has been engineered with specific exogenous genes (cytokines, immune checkpoint inhibitors, tumor antigens), creating a multi-functional composite therapeutic agent that simultaneously achieves rapid tumor cell lysis and long-term immune-mediated tumor suppression
2Productivity
If combination therapy with multiple treatment strategies is adopted, then anti-tumor effect is enhanced, but side effects increase
Solution Approach 1:
The patent segments the combination therapy into multiple distinct oncolytic virus agents, each engineered with specific exogenous genes for targeted functions. This segmentation allows each virus to contribute a specific therapeutic mechanism (e.g., one virus expresses cytokines for immune activation, another expresses immune checkpoint inhibitors), achieving synergistic anti-tumor effect while maintaining controlled and reduced side effects compared to conventional combination therapies
Solution Approach 2:
Each oncolytic virus in the composition is engineered with specific exogenous genes that provide localized therapeutic functions at the tumor site. The viruses deliver their therapeutic payloads specifically to tumor cells through selective infection, ensuring that the enhanced anti-tumor effect is achieved locally at the tumor while minimizing systemic side effects
3Productivity
If single oncolytic virus treatment is used, then treatment simplicity is maintained, but synergistic anti-tumor effect is insufficient
Solution Approach 1:
The patent merges multiple oncolytic viruses with different exogenous gene expressions into a single formulated composition. This merging allows the composition to deliver synergistic anti-tumor effects (combining direct cytolysis, immune activation, and checkpoint inhibition) while maintaining relative treatment simplicity through unified administration of the pre-formulated multi-virus composition
Data Source
AI summary
Provided is a recombinant oncolytic virus composition, comprising a first recombinant oncolytic virus and a second recombinant oncolytic virus. Both the first and second recombinant oncolytic viruses comprise a herpes simplex virus vector and an exogenous gene, the exogenous gene is encoded from one of cytokine, a monoclonal antibody having a tumor preventative and/or treatment function, tumor antigens, prodrug invertase, tumor suppressor polypeptide, antisense RNA or small RNA, wherein the exogenous genes in the first and the second recombinant oncolytic viruses are different. Also provided is an application of the recombinant oncolytic virus composition in preparation of a medicament drug for treating tumors.